Phase I Trial of OPB-111077 in Combination With Decitabine for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy

Trial Profile

Phase I Trial of OPB-111077 in Combination With Decitabine for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Decitabine (Primary) ; OPB 111077 (Primary)
  • Indications Myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2017 Status changed from active, no longer recruiting to recruiting.
    • 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2017 Status changed from discontinued to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top